- Home
- ACIC vs MLYS Comparison
ACIC vs MLYS Comparison
Compare ACIC & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACIC | MLYS |
|---|---|---|
| Founded | 1999 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 625.2M | 3.1B |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | ACIC | MLYS |
|---|---|---|
| Price | $12.86 | $37.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $47.33 |
| AVG Volume (30 Days) | 129.8K | ★ 1.6M |
| Earning Date | 11-05-2025 | 02-11-2026 |
| Dividend Yield | ★ 5.89% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | ★ $328,331,000.00 | N/A |
| Revenue This Year | $5.03 | N/A |
| Revenue Next Year | $2.40 | N/A |
| P/E Ratio | $7.35 | ★ N/A |
| Revenue Growth | ★ 22.22 | N/A |
| 52 Week Low | $9.97 | $8.24 |
| 52 Week High | $13.93 | $47.65 |
Technical Indicators
Market Signals| Indicator | ACIC | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 63.76 | 44.79 |
| Support Level | $12.66 | $36.01 |
| Resistance Level | $13.06 | $38.40 |
| Average True Range (ATR) | 0.25 | 1.79 |
| MACD | 0.06 | -0.05 |
| Stochastic Oscillator | 84.72 | 37.98 |
Price Performance
Historical ComparisonAbout ACIC American Coastal Insurance Corporation
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.